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drug sensitivity and resistance are conventionally quantified by ic 50 or E max values, but these metrics are highly sensitive to the number of divisions taking place over the course of a response assay. the dependency of ic 50 and E max on division rate creates artefactual correlations between genotype and drug sensitivity, while obscuring valuable biological insights and interfering with biomarker discovery. We derive alternative small molecule drug-response metrics that are insensitive to division number. these are based on estimation of the magnitude of drug-induced growth rate inhibition (Gr) using endpoint or time-course assays. We show that Gr 50 and Gr max are superior to conventional metrics for assessing the effects of small molecule drugs in dividing cells. moreover, adopting Gr metrics requires only modest changes in experimental protocols. We expect Gr metrics to improve the study of cell signaling and growth using small molecules and biologics and to facilitate the discovery of drug-response biomarkers and the identification of drugs effective against specific patient-derived tumor cells.
The quantification of drug response is fundamental to the discovery of therapeutic molecules, the investigation of their mechanisms of action [1] [2] [3] , and the study of signal transduction, cell division, and other biological processes using chemical biology approaches 4, 5 .
In the case of anticancer drugs, cells are typically exposed to drugs over a range of concentrations, and the number of viable cells (or surrogates, such as ATP level assayed using CellTiter-Glo, CTG) is measured several days later. Data comprising cell counts in the presence of drug divided by counts for untreated controls are fitted to a sigmoidal curve to compute (i) the concentration of drug at which the cell count is half the control (IC 50 ), (ii) the fraction of viable cells at the highest drug concentration (E max ), and (iii) the area under the dose-response curve (AUC) 6, 7 . Dose-response and genomic datasets are often combined to discover drug-response biomarkers [1] [2] [3] 8, 9 , but it has recently been found that large-scale drug-response data vary from one study to the next 10 for reasons that remain poorly understood [11] [12] [13] .
We show here that, for dividing cells, traditional drugresponse metrics such as IC 50 suffer from a fundamental flaw when they are estimated from cell counts made at the end of the experiment (the standard approach): if control cells undergo Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs Marc Hafner 1,2 , Mario Niepel 1,2 , Mirra Chung 1 & Peter K Sorger 1 different numbers of divisions during the course of an assay because of natural differences in proliferation rate, variation in growth conditions, or changes in the duration of an experiment, IC 50, E max , and AUC values will vary dramatically, independently of any changes in the underlying biology. Thus, biomarkers that predict sensitivity under one (potentially arbitrary) set of assay conditions may not predict sensitivity under slightly different conditions. We therefore propose a new method for parameterizing drug response, the normalized growth rate inhibition (GR), which is based on the comparison of growth rates in the presence and absence of drug. Parameterization of GR data yields GR 50 , GR max , GR AOC , and h GR (Hill slope), values that are largely independent of cell division rate and assay duration (we use 'area over the curve' , GR AOC , rather than AUC for reasons discussed in Online Methods). GR metrics can be determined with modest changes in experimental procedures, and we propose that these metrics replace IC 50 and E max values in assessing cellular response to drugs, RNAi, and other perturbations in which control cells divide over the course of the assay.
results definition of normalized growth rate inhibition (Gr)
We used computer simulation to model the drug response of three idealized cell lines with identical sensitivity to a cytostatic drug (i.e., a drug that arrests but does not kill cells) and different division times (T d = 1.8, 2.4, or 3.9 d). These division times correspond to the lower quartile, median, and upper quartile for breast cancer cell lines 3 and are similar to the division times of NCI-60 cells 14 .
In the slowly dividing cell line (T d = 3.9 d), the total number of cells did not double in an assay typically run over 3 days, and thus E max was ≥0.5, and IC 50 was undefined. In the case of the two faster-growing cell lines, IC 50 and E max values fell as division rate increased ( Fig. 1a ) because cell number (or CTG value) was normalized to a drug-naïve control in which cell number increased as division time fell (compare curves across panels of Fig. 1a) .
We can compensate for the confounding effects of division rate on drug-response measurements by computing the GR value at time t in the presence of drug at concentration c:
where k(c,t) is the growth rate of drug-treated cells and k(0) is the growth rate of untreated control cells (Fig. 1b) . The GR value is simply the ratio between growth rates under treated and untreated conditions normalized to a single cell division. The sign of the GR value relates directly to response phenotype: it lies between 0 and 1 in the case of partial growth inhibition, it equals 0 in the case of complete cytostasis, and it lies between 0 and −1 in the case of cell death. Given GR values for a range of drug concentrations, GR 50 is the concentration at which GR(c) = 0.5, GR max is the maximal measured GR value, and h GR is the slope of the sigmoidal fit; GR AOC is calculated by integrating the GR curve over a range of concentrations (Online Methods). In practice, GR values can be estimated from endpoint measurement of cell number in treated and untreated samples, given the initial cell number ( Fig. 1c ; this is related to the procedure for GI 50 determination, see Supplementary Note). Alternatively, the doubling time for untreated cells can be measured under the same conditions in parallel experiments and used in place of the initial cell number (Online Methods). A time-dependent GR value can be evaluated given cell count measurements at two or more time points. Time-dependent GR values capture adaptive responses, varying kinetics of drug-target interaction, drug efflux, etc. (Fig. 1d) . Introducing time as a variable makes it possible to relate drug-induced changes in cell states to dynamic measures of drug response at a molecular level (equations for all calculations are provided in Online Methods with links to scripts).
To compare GR dose-response curves to conventional curves, we created synthetic data for cells that had T d ranging from 1 to 4 d and that were exposed to a drug that was partially cytostatic, fully cytostasic, or cytotoxic (models are described in Online Methods). For all three drugs, IC 50 and E max values were strongly correlated with division time and assay duration, but this was not true of corresponding GR metrics ( Fig. 1e,f ; Supplementary  Fig. 1a,b; and Online Methods). In the case of drugs that kill cells rapidly and independently of cell cycle state, GR max still varies with growth rate, and time-dependent GR values are preferable ( Supplementary Fig. 2 and Online Methods). AUC combines IC 50 or E max data and is less sensitive to experimental noise 1,6,11 , but it suffers from the same dependence on cell division time; GR AOC corrects for this ( Supplementary Fig. 1c ).
Gr metrics are robust to experimental variability
To study how changing cell division affects IC 50 values, we expressed BRAF V600E in hTERT-immortalized retinal pigment epithelial (RPE) cells and then exposed them to etoposide, a topoisomerase II inhibitor that has a cytostatic effect in RPE cells (and whose mechanism of action is independent of BRAF). Oncogene overexpression is known to slow the growth of nontransformed cells 15, 16 , and expression of BRAF V600E in RPE cells under the control of a doxycycline-inducible promoter was observed to increase division time three-fold as the doxycycline concentration increased from 0 to 60 nM. Under these conditions the estimated IC 50 value for etoposide increased 100-fold and E max increased from 0.25 to 0.6 ( Fig. 2a and Supplementary  Fig. 3a) . In contrast, GR 50 and GR max values varied only slightly under these conditions because the effects of etoposide per cell division were unchanged.
In a second experiment, we measured etoposide sensitivity in MCF 10A cells grown in serum-free medium supplemented with different concentrations of epidermal growth factor (EGF). x 0
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The division time of MCF 10A cells varied from >10 d at 0.02 ng ml −1 EGF to <2 d at 1 ng ml −1 EGF ( Fig. 2c ). Across this range, IC 50 and E max for etoposide were substantially more variable than GR 50 or GR max values ( Fig. 2b and Supplementary  Fig. 3b ). Thus, potentially arbitrary and unintended differences in cell culture conditions can lead to large variation in IC 50 and E max values that is unlikely to have a biological basis.
To test the GR approach in a typical small-scale drug sensitivity screen, we exposed MCF 10A and BT-20 cells (expressing H2B-mCherry to facilitate automated cell counting) to five different drugs chosen for diverse mechanisms of action. We measured cell number approximately every 8 h over 3 d using an automated microscope. Estimated IC 50 and E max values converged only after three divisions (~60 h), whereas GR metrics stabilized by the first division (<20 h for MCF 10A and ~36 h for BT-20; Fig. 2c and Supplementary Fig. 3c ). This confirms that GR metrics are substantially less dependent on assay duration than are IC 50 and E max . In the case of very slow and uneven growth (by primary human tumor cells, for example), the stabilization of GR values within one cell division is likely to be a real advantage in obtaining reliable estimates of drug sensitivity.
When grown in 3D culture, MCF 10A cells are known to adapt to inhibitors of PI3K and mTOR (such as omipalisib), becoming less sensitive over time 17 . Endpoint measures of drug sensitivity do not report on such adaptive responses. However, when we monitored spheroids by live-cell imaging, we observed that the time-dependent GR and GR 50 values were lowest ~20 h after omipalisib addition, and they increased ~10-fold by day 4 (Fig. 2d) ; endpoint GR 50 values lay midway in this range ( Fig. 2d) . Thus, time-dependent GR data directly capture the decreasing effectiveness of omipalisib in MCF 10A spheroids, enabling detection and further analysis of adaptive mechanisms.
Analysis of high-throughput data using Gr metrics
The majority of large-scale drug-response datasets published to date neither report cell division rates nor allow one to estimate them. An exception is a study by Heiser et al. 3 , which recorded cell numbers for breast cancer cell lines before and after exposure to a panel of anticancer drugs for 3 days. For many drugs in this dataset, IC 50 correlates with division rate 6 (e.g., for cell cycle inhibitors, regression coefficient of −0.54, Spearman's P-value < 10 −66 , N = 2,956; npg Supplementary Fig. 4a ). However, we could reproduce this correlation by using an idealized model that does not assume any biological connection between drug sensitivity and division rate and by repeatedly simulating drug responses using random parameters ( Supplementary Fig. 4b and Online Methods). This finding suggests that the correlation between drug sensitivity and division rate found in experimental data is spurious; also, the correlation was absent when drug response was measured using GR 50 (Spearman's P-value = 0.31, Supplementary Data 1), suggesting that it is an artifact of the way IC 50 is calculated. Paclitaxel, a taxane microtubule inhibitor widely used in chemotherapy, is one drug that exhibits a strong negative correlation between sensitivity and division rate as well as substantial variation (100-fold) in IC 50 across cell lines (Fig. 3a) . This relationship has previously been described and is thought to arise because paclitaxel acts primarily on mitotic cells, and the faster a cell line divides, the more likely it is to be in mitosis 18, 19 . However, reanalysis of data in Heiser et al. 3 shows that GR 50 values for paclitaxel actually span a narrow range centered around 10 nM ( Fig. 3b and Supplementary Fig. 4c ), close to the estimated affinity of paclitaxel for assembled microtubules in vitro 20 . In contrast, GR max values for paclitaxel vary considerably across cell lines and subtypes. In HER2-amplified (HER2 amp ) and triple-negative breast cancer (TNBC) lines GR max values are negative, which is indicative of a cytotoxic response, whereas hormone receptorpositive (HR + ) and nonmalignant lines generally exhibit cytostatic responses (Supplementary Fig. 4c ). This is consistent with data showing that HER2 amp and TNBC (basal-like) human tumors are more taxane-sensitive than tumors in other types of breast cancer 21 . We propose that future attempts to find biomarkers predictive of paclitaxel response focus on variation in GR max rather than variation in IC 50 22, 23 . The average division rate of breast cancer cell lines in culture differs with clinical subtype: among cells studied by Heiser et al. 3 , HR + and HER2 amp subtypes divided most slowly (median T d = 3.2 d), TNBC cells divided faster (median T d = 2.3 d), and nonmalignant cells divided still faster (median T d = 1.8 d, Fig. 3c ). As measured by IC 50 values, nonmalignant cells were, on average, more sensitive to anticancer drugs than tumor cells, whereas GR 50 values showed that the mean and range of drug sensitivity was similar ( Fig. 3d) . Focusing on HER2 amp lines, IC 50 values for inhibitors of EGFR and ErbB2 were similar across breast cancer subtypes, even though HER2 amp human tumors are preferentially sensitive to such drugs and ErbB2 inhibitors are frontline therapy for this disease 24, 25 . GR 50 data for HER2 amp cell lines in Heiser et al. show that this subtype of breast cancer is ~10-fold more sensitive than other subtypes to EGFR/ErbB2 inhibitors in vitro ( Fig. 3e ; P = 1.3 × 10 −4 ). The failure of IC 50 values to show the preferential sensitivity of HER2 amp cell lines to EGFR/ErbB2 inhibitors arises because their relatively slow growth rate is a hidden confounder in IC 50 calculation. From these data we conclude that artefactual dependency of IC 50 on cell division rate creates associations where none exist and also obscures meaningful associations between genotype and drug sensitivity. npg effects of cell density on drug sensitivity GR metrics allow us to quantify how drug sensitivity changes in the face of variables that affect division rate. One such variable is seeding density: increasing density has widely been reported to promote drug resistance [26] [27] [28] [29] . To investigate this, we cultured six breast cell lines representative of different subtypes at six seeding densities over a 32-fold range. 24 h after plating, cells were exposed to 11 drugs with diverse mechanisms of action. Growth rates, IC 50 , E max , and GR metrics were estimated by imaging and counting fixed cells at the time of drug addition and 72 h after treatment (Supplementary Data 2) . Overall, IC 50 and E max correlated positively with seeding number for MCF 10A, MDA-MB-231, and Hs 578T cells, and they correlated negatively for BT-20 and SK-BR-3 cells (P < 0.01, Fig. 4a ). In the first three cell lines, division rate decreased with density, presumably because of contact inhibition, depletion of essential medium components, and other effects (Fig. 4b) [30] [31] [32] . In BT-20 and SK-BR-3 cells, division rate increased with density, presumably because of conditioning of the growth medium 31, 33 .
Correlations between density and IC 50 and E max were weakest for MCF7 cells, which grew equally well across all densities. Thus, the effect of density on number of divisions, and consequently on IC 50 and E max , varied dramatically among cell lines (Supplementary Fig. 5a) . However, only a small number of cell line-drug pairs exhibited a statistically significant association between plating density and GR 50 or GR max values. We wondered whether these were situations in which the biology of drug response was altered by density. In MCF 10A cells, six drugs were associated with significant variation in GR 50 or GR max (or both) across seeding densities; RNA-seq revealed that gene expression in these cells also varied with cell density, with significant enrichment for genes involved in catabolic processes, cellular respiration, and wounding responses [30] [31] [32] 34 (Supplementary Fig. 6a ). When the data was analyzed by principal-component analysis, the first principal component (which captured 32% of variance) was strongly correlated with the number of cells at the time of collection (Spearman's ρ = 0.98) and less so with time in culture (ρ = 0.57), suggesting that the cell density at the time of assay and not the history of the culture was the primary determinant of transcriptional state (Supplementary Fig. 6b) . Follow-up studies with methotrexate showed that the ratio between cell number and medium volume, and not cell density per se, was the key variable for sensitivity to this drug (this was also true of oligomycin, an inhibitor of ATP synthase; Fig. 5a and Supplementary Fig. 7) ; since cells grew in a constant volume of medium, GR 50 was therefore time dependent. Density-(and time-) dependent variation in GR 50 were also observed for linsitinib, an IGF1R inhibitor currently in Phase II clinical trials (Fig. 5b) . Variation in GR 50 with time and density was reduced by cotreatment with the metalloprotease inhibitor npg batimastat, suggesting a role for autocrine conditioning of the microenvironment in drug response.
In the case of paclitaxel, GR 50 values remained at ~5-10 nM across plating densities, but GR max was strongly density dependent, varying from ~0 (cytostatic) at low cell densities to negative values (cytotoxic) at higher densities (Fig. 5c, left) . Time-dependent GR max reached its greatest negative value at 24 h, concomitant with an increase in the fraction of taxol-treated cells that contain cleaved caspase-3, confirming that negative GR max values corresponded to elevated apoptosis (Fig. 5c, middle and right) . Though its molecular basis is unknown, this effect may be one reason for the discrepancy between cell-killing dynamics in low-density culture and in high-density xenograft tumors 35 .
discussion Accurate measurement of drug sensitivity and resistance is the cornerstone of cancer biology, pharmacology, and of many fundamental studies on cell signaling and cell division. In this paper we demonstrate theoretically and experimentally that variation in division rate seriously confounds existing drug-response metrics. We also show that division rate varies with cell type, medium composition, and seeding density, often in unpredictable ways. Cell division rate slows down in some cell lines as density increases, while it speeds up in others. Such variation can change apparent IC 50 100-fold or more and therefore introduce artificial correlations in data, obscure the true effects of drug action, and introduce unknown complications into biomarker discovery. As an alternative, we propose GR metrics that are computed by comparing growth rates in the presence and absence of drug. GR 50 and GR max are robust to variation in cell division rate and should replace IC 50 and E max in studies in which control cells divide (including the study of drugs, gene depletion or overexpression, and variation in the extracellular environment). GR 50 quantifies the potency of a drug on a per-division basis, ensuring that fastand slow-growing cells with similar biochemical responses to drug are scored equivalently. GR max captures the maximal drug effect on growth rate and differs from E max in that it falls between 1 and −1, where negative values denote cell death, 0 denotes cytostasis, and positive values denote partial inhibition. GR AOC and h GR values can also be calculated from GR curves; the former is often the most robust metric in the face of experimental noise, and the latter quantifies an important relationship between dose and response that is often neglected 6 .
In the simplest version of our method, GR metrics are computed after measuring cell number or a surrogate (e.g., CTG value) before and after exposure of a culture to varying concentrations of drug or other perturbation for a fixed time (Fig. 1c) . When cell division rates under similar culture conditions are known from previous data, only the final cell number is needed (although we believe that before and after data on cell number are a valuable control to ensure data quality). Time-course data make it possible to compute time-dependent GR values and to quantify phenomena such as delayed response, drug adaptation, or variation in the kinetics of drug-target interaction (Fig. 1d) .
To facilitate the use of GR metrics by others we provide MATLAB and python routines and an online GR calculator (http://www. grcalculator.org/). Moreover, the data in this paper, including the GR 50 and GR max values for the Heiser et al. dataset, are available online (http://lincs.hms.harvard.edu/). Large-scale drug-response studies based on existing response metrics 1, 2, 8, 9 are discrepant for poorly understood reasons 5, 11, 12 , raising concerns about the value of drug-response biomarkers 10 . We speculate that comparison of datasets across centers (or even within a center) might be confounded by differences in plating density, growth medium, and other factors that affect cell division rate. It might be possible to correct for this in existing data by computing GR values post facto, but this will require recreating the original assay conditions and then measuring division rates.
Based on the results in this paper, we believe that use of GR metrics in lieu of traditional IC 50 , E max , or AUC values will improve our ability to identify genes and biological processes responsible for drug sensitivity and resistance. GR metrics decouple any effect that genotype or microenvironment have on division rate from their effect on drug sensitivity. Cell biology studies involving the modification of genes or the microenvironment often result in changes in cell division rate, leading to potentially spurious correlations with drug sensitivity (as illustrated here by oncogene overexpression and changes in EGF levels), and should also benefit from the use of GR metrics. By analogy with antimicrobial susceptibility testing for bacterial infections, it has recently been suggested that cancer therapy might be personalized by screening primary human tumor cells against panels of drugs 36, 37 . Such cells grow slowly and unevenly in culture, making division number a poorly controlled variable. Accounting for such differences using GR metrics should create drug-response data that are more reproducible and useful for optimizing patient therapy.
methods
Methods and any associated references are available in the online version of the paper.
Accession codes. Data are deposited in the Gene Expression Omnibus (GEO) database with accession number GSE80297.
Note: Any Supplementary Information and Source Data files are available in the online version of the paper. online methods Metrics of drug response. Determining relative cell counts. Cell counts in the presence of drug are normalized to DMSO-treated controls grown on the same plate under the same conditions. In the current study, relevant conditions include seeding density, the concentration of exogenous growth factors (e.g., EGF in the case of MCF 10A cells), and the concentration of a second drug such as doxycycline or batimastat. For each cell line, drug, and drug concentration, we define the relative cell count as x(c)/x ctrl , where x(c) is the count in the presence of drug at concentration c and x ctrl is the 50%-trimmed mean of the count for control cells. Technical replicates are averaged to yield an average relative cell count. We typically collect data from three technical replicates (on three separate plates).
Calculating GR values using endpoint drug-response data.
Normalized growth rate inhibition is calculated according to the formula: Fig. 1d) .
The time-dependent GR values in the current paper were computed with 2 × ∆t = 12 h to 18 h, which corresponds to about half a cell division time.
Curve fitting and estimating drug-response metrics. GR data are fitted to a sigmoidal curve as follows (Supplementary Fig. 8b) :
where the fitted parameters are:
• GR inf : the effect of the drug at infinite concentration (GR inf ≡ GR (c → )). GR inf lies between −1 and 1; negative values correspond to cytotoxic responses (i.e., induction of cell death, Supplementary  Fig. 8a) , a value of 0 corresponds to a fully cytostatic response (Supplementary Fig. 8b) , and a positive value corresponds to partial growth inhibition (Supplementary Fig. 8c ).
• h GR : the Hill coefficient of the fitted curve, which reflects how steep the dose-response curve is. In practice, we typically constrain h GR to a value between 0.1 and 5. • GEC 50 : the concentration at half-maximal effect. To avoid artefacts in curve fitting we constrain GEC 50 to be two orders of magnitude higher and lower than the experimentally tested concentration range (in practice, this is usually about 10 −5 to 10 3 µM).
If the fit of the curve is not significantly better than that of a flat curve (i.e., GR(c) ≡ GR inf ) based on an F-test with cutoff of P = 0.05, the response is considered flat and the parameter GEC 50 is set to 0 (Supplementary Fig. 8d ).
Inferred drug-response metrics. The GR 50 value is the concentration of drug at which GR(c = GR 50 ) = 0.5. If the value for GR inf is above 0.5, the GR 50 value is not defined and is therefore set to + (Supplementary Fig. 8c ). By extension, other thresholds can be defined in a similar manner. For example, GR 100 corresponds to the concentration at which a drug is fully cytostatic: GR(c = GR 100 ) = 0.
The GR max is the maximum effect of the drug at the highest tested concentration, and it lies between −1 and 1; a value of 0 corresponds to a fully cytostatic response, and a negative value corresponds to a cytotoxic response. GR max can be estimated from the fitted curve or obtained directly from experimental data; we often do the latter.
For time course data, all metrics are evaluated at each time point individually.
Area under the curve and over the curve (GR AOC ). Another common metric for quantifying dose-response data is the area under the response curve (AUC), which is based on integrating the dose-response curve over the range of tested concentrations. In the case of GR curves, which can have negative values, it is more intuitive to use the area over the curve:
where GR(c i ) are measured GR values at discrete concentrations c i . GR AOC has the benefit that, in the case of no response, it has a value of 0. The GR AOC can be normalized to the range of concentrations as, for example, GR AOC /log 10 (c max /c min ), where c max and c min are the highest and lowest tested concentrations. It is important to note that GR AOC values (like conventional AUC) should only be used to compare responses evaluated across the same drug concentration range. The GR AOC value captures variation in potency and efficacy at the same time. The calculation of GR AOC at discrete (experimentally determined) concentrations has the advantage that it does not require curve fitting and is therefore free of fitting artifacts. This is especially useful for assays where fewer than five concentrations are measured, and curve fitting is unreliable. GR AOC values are also more robust to experimental noise than metrics derived from curve fitting; GR max values are particularly sensitive to outlier values when directly obtained from data.
npg Drug concentration range. The drug concentrations used for fitting drug-response curves need to span a sufficiently wide range and have sufficiently intermediate values in order to obtain reliable estimates for GEC 50 , h GR , and GR inf . Denser sampling provides more precise estimates, especially in the case of steep dose-response curves. Optimal design of dose-response curves has been discussed elsewhere 7 . In practice, we suggest using nine doses spanning four orders of magnitude from 1 nM to 10 µM. This range can be shifted to lower concentrations for more potent drugs or to higher concentrations for less potent drugs with the caveat that GR AOC values for different drugs should be compared only if evaluated over the same concentration range. We suggest discarding any GR 50 value that is more than an order of magnitude above the highest tested concentration because values extrapolated from the fitted curves are more subject to fitting artefacts than interpolated values. Similarly, GR inf value is not properly constrained if the GR(c) dose-response curve does not reach a plateau at the highest measured concentration. In such cases, GR AOC is the most reliable metric. Software) . To facilitate the computation of GR metrics we provide updated source code available under an open source software license and MATLAB and python scripts at https://github.com/sorgerlab/gr50_tools. We also provide an online calculator at http://www.grcalculator.org. This website contains a user guide, various tutorials and explanatory materials, and example datasets, including all of the data in the current manuscript.
Computing GR metrics. Source code for computing GR metrics is provided (Supplementary
Theoretical model of drug response. To simulate the effect of division time on GR and conventional drug-response metrics under different assumptions about the degree of cytostasis or cell killing, we developed a theoretical model of drug response. To the first approximation, cell growth can be considered exponential, with drugs either decreasing the division rate or killing cells in a cell-cycle-dependent manner:
where x is the cell count, k is the untreated growth rate (per day), c is the drug concentration, S M is the maximal inhibitory effect, SC 50 is the concentration at half-maximal effect of drug, and h is the Hill coefficient. The growth rate k corresponds to the division rate k 0 as k = ln(2) × k 0 = ln(2)/T d , where T d is the division time. S M can be larger than 1 to account for drugs inducing cell death at a specific phase of the cell cycle. The model can also be generalized to account for drugs that induce cell death independent of the cell cycle: Manipulating cell growth rate to determine effects on drug sensitivity. RPE-1 or MCF 10A-H2B-mCherry cells were plated in 384-well plates using the Multidrop Combi Reagent Dispenser (Thermo Scientific) at 250 and 500 cells per well, respectively. To modulate the growth rate in RPE-1 cells, we induced expression of the BRAF V600E oncogene by treating cells with indicated doses of doxycycline using a D300 Digital Dispenser (Hewlett-Packard).
To modulate the growth rate in MCF 10A-H2B-mCherry we serum-starved cells twice with DMEM/F12 medium supplemented with 0.1% bovine serum albumin and 1% penicillinstreptomycin. Medium changes and cell washing were performed using an EL406 Microplate Washer Dispenser (BioTek). Cells were treated with indicated doses of human epidermal growth factor (EGF, Peprotech) using a D300 Digital Dispenser. After 24 h the cells were treated with a dilution series of etoposide using a D300 Digital Dispenser. RPE-1 cells were stained and fixed for analysis at the time of drug treatment and after 72 h. MCF 10A-H2B-mCherry cells were imaged in an IncuCyte ZOOM live-cell imager (Essen Bioscience) starting at the time of EGF treatment, and drug sensitivity was evaluated 72 h after drug addition.
Evaluating drug-response metrics in MCF 10A and BT-20 over time. MCF10 A-H2B-mCherry and BT-20-H2B-mCherry cells were plated at 1,250 and 2,500 cells per well, respectively, in 384-well plates using the Multidrop Combi Reagent Dispenser (Thermo Scientific) and grown for 24 h. Cells were treated with a dilution series of the indicated drugs using a D300 Digital Dispenser (Hewlett-Packard) and imaged after drug addition in an Operetta High-Content Imaging System (PerkinElmer) equipped with a live-cell chamber over a period of 96 h. For these experiments, we used the following drugs: Evaluating drug sensitivity in breast cancer cells plated at different seeding densities. MCF 10A, Hs 578T, MDA-MB-231, MCF7, SK-BR-3, and BT-20 were plated at densities ranging from 156 to 5,000 cells per well in 384-well plates using the Multidrop Combi Reagent Dispenser (Thermo Scientific) and grown for 24 h. Cells were treated with a dilution series of the indicated drugs using a D300 Digital Dispenser (Hewlett-Packard). Cells were stained and fixed for analysis at the time of drug treatment and after 72 h of incubation with drug. For these experiments, we used the following drugs: Investigating density-dependent drug effects. MCF 10A-H2B-mCherry cells were plated at densities that ranged from 156 to 5,000 cells per well in 384-well plates using the Multidrop Combi Reagent Dispenser (Thermo Scientific) and grown for 24 h. Cells were treated with a dilution series of drugs using a D300 Digital Dispenser (Hewlett-Packard) and imaged after drug addition in an Operetta High-Content Imaging System (PerkinElmer) equipped with a live-cell chamber over a period of 72 h. In the case of methotrexate and oligomycin, 1,250 cells were plated in 20-120 µL of medium per well, treated with a dilution series of drug, and imaged for 72 h.
